Stefanie S. Schalm

5.3k citations

19 papers · 2.0k indexed · 1 hit paper · h-index 13

Molecular Biology top 5%
Oncology top 10%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 5%
Immunology

Co-authors: John Blenis Joseph L. Kim Ethan Cerami Nicolas Stransky Christoph Lengauer David M. Sabatini Diane C. Fingar Celeste Richardson
Topics: Lung Cancer Treatments and Mutations (7 papers)PI3K/AKT/mTOR signaling in cancer (5 papers)Colorectal Cancer Treatments and Studies (4 papers)
Cited by: Molecular Biology Cancer Research Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Communications
Partner nations: United States South Korea Germany

In The Last Decade

Stefanie S. Schalm

19 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The landscape of kinase fusions in cancer

2014 657 citations Nicolas Stransky, Ethan Cerami et al. Nature Communications profile →

Peers

Countries citing papers authored by Stefanie S. Schalm

Since Specialization

Citations

This map shows the geographic impact of Stefanie S. Schalm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefanie S. Schalm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefanie S. Schalm more than expected).

Fields of papers citing papers by Stefanie S. Schalm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefanie S. Schalm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefanie S. Schalm. The network helps show where Stefanie S. Schalm may publish in the future.

Co-authorship network of co-authors of Stefanie S. Schalm

This figure shows the co-authorship network connecting the top 25 collaborators of Stefanie S. Schalm. A scholar is included among the top collaborators of Stefanie S. Schalm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefanie S. Schalm. Stefanie S. Schalm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer 2024 ·Therapeutic Advances in Medical Oncology ·Sun Min Lim,Stefanie S. Schalm,(unknown),Sewon Park,Chiara Conti,Yves Millet,Rich Woessner,Zhuo Zhang,Luz E. Tavera-Mendoza,Faith Stevison,Faris Albayya,Thomas A. Dineen,(unknown),(unknown),Alena Zalutskaya,Julia Rotow,Kōichi Goto,Dae-Ho Lee,Mi Ran Yun,Byoung Chul Cho	7
2	P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS. 2023 ·HemaSphere ·Stefanie S. Schalm,Yogesh K. Chutake,Susanne B. Breitkopf,Michele Mayo,Nancy Dumont,Dapeng Chen,Vaishali Dixit,Rahul Karnik,Alice McDonald,(unknown),William Proctor,(unknown),Kan‐Nian Hu,(unknown),Ashwin Gollerkeri,Kirti Sharma,Joseph D. Growney,Juliet A. Williams	1
3	Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia 2022 ·Blood ·Michele Mayo,Yogesh K. Chutake,Rahul Karnik,Alice McDonald,Patricia S. Cho,(unknown),Dapeng Chen,Vaishali Dixit,William Proctor,Susanne B. Breitkopf,(unknown),Kan‐Nian Hu,Kirti Sharma,(unknown),(unknown),Joseph D. Growney,Juliet A. Williams,Stefanie S. Schalm	9
4	Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC 2022 ·Cancer Research ·(unknown),Stefanie S. Schalm,John Campbell,Jian Guo,(unknown),(unknown),Faris Albayya,(unknown),Zhuo Zhang,Maria S. Iliou,(unknown),(unknown),Yoav Timsit,Scott Wardwell,(unknown),Richard Woessner,Chiara Conti	9
5	Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC) 2021 ·Cancer Research ·Sun Min Lim,Chae Won Park,Zhuo Zhang,Rich Woessner,(unknown),Faith Stevison,(unknown),(unknown),(unknown),John Campbell,(unknown),Faris Albayya,(unknown),Marion Dorsch,Klaus P. Hoeflich,Byoung Chul Cho,Stefanie S. Schalm	17
6	1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC 2020 ·Annals of Oncology ·Stefanie S. Schalm,(unknown),Sangbin Lim,(unknown),(unknown),Rich Woessner,(unknown),Kevin Wilson,(unknown),Douglas Wilson,Brett Williams,John Campbell,Chris De Savi,Faith Stevison,(unknown),(unknown),Marion Dorsch,Klaus P. Hoeflich,(unknown)	43
7	384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC 2020 ·Annals of Oncology ·Stefanie S. Schalm,(unknown),Sangbin Lim,(unknown),(unknown),Rich Woessner,(unknown),Kevin Wilson,(unknown),Douglas Wilson,Brett Williams,John Campbell,Chris De Savi,Faith Stevison,(unknown),(unknown),Marion Dorsch,Klaus P. Hoeflich,Byoung Chul Cho	12
8	Abstract 954: The landscape of kinase fusions in cancer 2015 ·Cancer Research ·Nicolas Stransky,Ethan Cerami,Stefanie S. Schalm,Joseph L. Kim,Klaus P. Hoeflich,Christoph Lengauer	1
9	The landscape of kinase fusions in cancerbreakdown → 2014 ·Nature Communications ·Nicolas Stransky,Ethan Cerami,Stefanie S. Schalm,Joseph L. Kim,Christoph Lengauer	657
10	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition 2014 ·Blood ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	128
11	Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition 2014 ·Cancer Research ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	1
12	Phosphorylation of protocadherin proteins by the receptor tyrosine kinase Ret 2010 ·Proceedings of the National Academy of Sciences ·Stefanie S. Schalm,Bryan A. Ballif,Sean M. Buchanan,Greg R. Phillips,Tom Maniatis	50
13	Proteolytic processing of protocadherin proteins requires endocytosis 2010 ·Proceedings of the National Academy of Sciences ·Sean M. Buchanan,Stefanie S. Schalm,Tom Maniatis	35
14	Characterization of a Conserved C-terminal Motif (RSPRR) in Ribosomal Protein S6 Kinase 1 Required for Its Mammalian Target of Rapamycin-dependent Regulation 2005 ·Journal of Biological Chemistry ·Stefanie S. Schalm,Andrew R. Tee,John Blenis	45
15	PI3-kinase and TOR: PIKTORing cell growth 2004 ·Seminars in Cell and Developmental Biology ·Celeste Richardson,Stefanie S. Schalm,John Blenis	111
16	TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function 2003 ·Current Biology ·Stefanie S. Schalm,Diane C. Fingar,David M. Sabatini,John Blenis	395
17	Identification of a Conserved Motif Required for mTOR Signaling 2002 ·Current Biology ·Stefanie S. Schalm,John Blenis	364
18	Regulation of Ribosomal S6 Kinase 2 by Effectors of the Phosphoinositide 3-Kinase Pathway 2001 ·Journal of Biological Chemistry ·Kathleen A. Martin,Stefanie S. Schalm,Celeste Richardson,Angela Romanelli,(unknown),John Blenis	53
19	Ribosomal S6 Kinase 2 Inhibition by a Potent C-terminal Repressor Domain Is Relieved by Mitogen-activated Protein-Extracellular Signal-regulated Kinase Kinase-regulated Phosphorylation 2001 ·Journal of Biological Chemistry ·Kathleen A. Martin,Stefanie S. Schalm,Angela Romanelli,(unknown),John Blenis	57

About Stefanie S. Schalm

Stefanie S. Schalm is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 19 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). The work is most often cited by research in Molecular Biology (1.5k citations), Cancer Research (309 citations) and Oncology (428 citations). Stefanie S. Schalm has collaborated with scholars based in United States, South Korea and Germany. Frequent co-authors include John Blenis, Joseph L. Kim, Ethan Cerami, Nicolas Stransky, Christoph Lengauer, David M. Sabatini, Diane C. Fingar, Celeste Richardson, Sean M. Buchanan and Tom Maniatis. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact